金葡素联合顺铂与顺铂单药控制恶性胸腹水疗效的Meta分析

目的:评价金葡素联合顺铂与顺铂单药治疗恶性胸腹水的有效性与安全性。方法:检索中国生物医学文献数据库（1990-2014）、中国期刊全文数据库（1990-2014）、维普数据库（1990-2014.12）、万方数据库（1990-2014.12）、PubMed （1990-2014.12）、Cochrane Library（1990-2014.12）纳入金葡素联合顺铂（试验组）与顺铂单药（对照组）治疗恶性胸腹水的随机对照试验（RCT），采用Jadad改良法制定的量表评价纳入研究的质量，RevMan 5.2进行Meta分析。结果:共检索到文献100篇，按照纳入与排除标准共纳入文献16篇。Meta分析结果:金葡素联合顺铂用药治疗恶性胸腹水有效率上明显优于顺铂单药［OR=2.12，95%CI（1.64，2.74），P<0.000 01］，金葡素联合顺铂较顺铂单药组易引起发热［OR=2.26，95%CI(1.36，3.75)，P=0.002］，但两组在胸闷胸痛［OR=1.09，95%CI(0.55，2.17)，P=0.81］发生率上无明显差异，在胃肠道反应［OR=0.34，95%CI(0.18，0.64)，P=0.000 7］、白细胞下降［OR=0.27，95%CI(0.16，0.46)，P<0.000 01］发生率上金葡素联合顺铂组明显低于顺铂单药组，且在改善患者生活质量上优于顺铂单药［OR=4.83，95%CI(2.96，7.87)，P<0.000 01］。结论:金葡素联合顺铂较顺铂单药组在治疗恶性胸腹水上更为有效，并且毒副反应轻，安全性高。

Meta -analysis of the treatment efficacy of staphylococcin plus cisplatin versus cisplatin monotherapy in malignant pleural effusion and malignant intraperitoneal effusion

Objective:To evaluate the efficacy and safety of staphylococcin plus cisplatin versus cisplatin mono-therapy treating malignant pleural and intraperitoneal effusion.Methods:The data of the randomized controlled trial (RCT)of staphylococcin plus cisplatin(experimental group)vs cisplatin alone(control group)in the treatment of malignant pleural and intraperitoneal effusion was searched in Chinese Biomedical Literature Database (1990 -2014),China Academic Journal(1990 -2014),VIP database(1990 -2014.12),Articles Database(1990 -2014. 12),PubMed(1990 -2014.12),Cochrane Library(1990 -2014.12).The quality of the RCT was evaluated by the Jadad scale evaluation method.The Meta -analysis was performed by RevMan 5.2.Results:16 literature was selected from a total of 100 retrieved documents.Staphylococcin combined with cisplatin in the treatment of malignant pleural and intraperitoneal effusion was superior to cisplatin monotherapyOR =2.12,95%CI(1.64,2.74),P <0.000 01]. The combination group more easily caused a feverOR =2.26,95%CI(1.36,3.75),P =0.002],but the two groups had no significant difference in the incidence of chest painOR =1.09,95%CI(0.55,2.17),P =0.81].The inci-dence of staphylococcin plus cisplatin was superior to cisplatin monotherapy in the gastrointestinal tractOR =0.34, 95%CI(0.18,0.64),P =0.000 7],leukopeniaOR =0.27,95%CI(0.16,0.46),P <0.000 01]and in improving the quality of life of patientsOR =4.83,95%CI(2.96,7.87),P <0.000 01 ].Conclusion:Staphylococcin com-bined with cisplatin was superior to cisplatin monotherapy not only in the treatment of malignant pleural and intraper-itoneal effusion,but also have less mild side effects and more safe.